Put Yourself In The CEO’s Shoes: Audience Makes Drug Pricing And Investment Decisions At EHFG
Executive Summary
A pricing simulation exercise at the recent EHFG conference gave delegates an idea of the multiple factors that have to be taken into account when setting the price of a new drug for a rare disease – and deciding which candidate molecules are worth investing in.
You may also be interested in...
Scrip Company Of The Year Celgene In Rude Health Despite Hiccups
Celgene, which continues to plough back a very high proportion of its revenues into R&D, remains the preferred partner of choice for biotechs who hope to bring the next wave of innovative products to the market, Kevin Loth, VP of corporate affairs and policy in Europe tells Scrip.
What EU Governments Need To Do About Access To Affordable Medicines
In a wide-ranging discussion at the recent European Health Forum Gastein, policy makers explored big-picture challenges and ideas of what governments should do to ensure access to increasingly expensive medicines as pressures grow on national health care systems.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.